Pediatric Hematology and Oncology
- Assistant Professor, Department of Pediatrics
EDWARD CHAN MD
- AFFINITY HEALTH PLAN
- BEECH STREET
- CIGNA GREAT WEST HEALTHCARE
- CIGNA HMO
- CIGNA PPO
- EMBLEM GHI CBP
- EMBLEM HIP-HMO
- EMBLEM HIP-MEDICAID
- EMBLEM HIP-MEDICARE
- EMPIRE BLUE CHOICE HMO
- EMPIRE BLUE CHOICE INDEMNITY PLANS
- EMPIRE BLUE CHOICE PPO
- FIDELIS CARE NEW YORK
- ISLAND GROUP ADMINISTRATION
- MAGNACARE HEALTH REPUBLIC EXCHANGE
- MULTIPLAN PHCS
- MULTIPLAN SAVILITY
- UNITED EMPIRE PLAN (NYSHIP)
- UNITED HEALTHCARE
- UNITED OXFORD FREEDOM PLAN
- UNITED OXFORD LIBERTY PLAN
- US FAMILY HEALTH PLAN
- VISITING NURSE SERVICES (FIDA)
- VYTRA (except SMART START)
Education & Training
- State University of New York at Buffalo, NY
- Pediatrics, Children's Hospital of Buffalo, NY
Pediatric Hematology/Oncology, Cincinnati Children's Hospital Medical Center, OH
Academic & Other
- Academic Rank:
- Assistant Professor
- Teaching Activity:
- Undergraduate, graduate and medical students; pediatric residents
- Year Appointed at
(1)2014-16 NIH/NCI-R21 Award: Validation of Molecular Diagnostics to Predict Patient Outcomes Using Specimens from Multi-Site Cancer Trials
(2)2009-15 American Cancer Society Mentored Research Scholar Grant in Applied and Clinical Research
(3)2012-14 Clinical Research Award, TRO Grant Program
(4)2010-11 Catacosinos Cancer Translational Researcher Award
(5)2009-12 NIH/NCI-R21 Award: Exploratory Studies in Cancer Detection, Diagnosis, and Prognosis
(6)2007-09 NIH Pediatric Research LRP Award
(7)2006-08 Clinical Scholar Research Award, Stony Brook SOM
(8)2005-07 Carol M. Baldwin Breast Cancer Research Award
Children's Oncology Group
There are two areas of interest in our research program. The first is the investigation into the mechanisms by which tyrosine kinase receptors affect tumor growth, malignant transformation and cancer cells' response to chemotherapy. The second focuses on translating the findings of these mechanistic studies to personalized target therapy for patients with cancers. Our long term goal is to facilitate the rapid translation of basic science discoveries to innovative cancer clinical trials.
- Clinical Practice Began:
- Cantonese, Chinese
3 EDMUND D PELLEGRINO RD,
(1)Etheridge SL, Cosgrove ME, Sangkhae V, Corbo LM, Roh ME, Seeliger MA, Chan EL, Hitchcock IS. A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. Blood, 2014 Feb 13;123(7):1059-68.
(2)Keller J, Nimnual AS, Shroyer KR, Joy C, Ischenko I, Chandler CS, Dong LM, HaymanMJ, Chan EL. Ron tyrosine kinase receptor synergies with EGFR to confer adverse features in head and neck squamous cell carcinoma. British Journal of Cancer, 2013 Jul 23;109(2):482-92.
(3)Hu Y, Ahmed T, Zaslav AL, Golightly M, Spitzer SG, Raetz E, Chan EL. Lymphoproliferative disorder that resembles heptosplenic lymphoma during maintenance treatment for T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013 Jun;60(6):E10-2. doi: 10.1002/pbc.24442.
(4)Sarangi SN, Golightly M, Weber J, Chan EL. A family with Bolzano-type Bernard-Soulier syndrome carries a benign A1939T MYH9 mutation. Platelets. 2013;24(1):81-4.
(5)Keller J, Shroyer KR, Batajoo SK, Zhao HL, Dong LM, Hayman MJ, Chan EL. Combination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancer. Cancer Investigation 2010 Dec;28(10):1054-62.
(6)Chan E, Nimnual AS. Deregulation of the cell cycle by breast tumor kinase (Brk). Int J Cancer 2010 Dec 1;127(11):2723-31.
(7)Chan EL, Gruppo RA, Harris RE, Emery KH, Gelfand MJ and Collins MH. Favorable Histology, MYCN Amplified, 4S Neonatal Neuroblastoma. Pediatric Blood and Cancer April 2007;48(4):479-82.
(8)Chan EL, Peace BE, Collins MH, Toney-Earley K and Waltz SE. The Ron tyrosine kinase receptor regulates papilloma growth and malignant conversion in a murine model of skin carcinogenesis. Oncogene 2005;24(3):479-88.
(9)Chan EL, Peace BE, Collins MH, Toney-Earley K and Waltz SE. Homozygous K5Cre transgenic mice have pronounced wavy hair and associated with accelerated malignant progression in a murine model of skin carcinogenesis. Molecular Carcinogenesis Jan 2007;46(1):49-59.
Dr. Chan is a board certified pediatric hematologist/oncologist whose laboratory investigates tyrosine kinase receptors as biomarkers and therapeutic targets. Our long term goal is to develop personalized molecular target therapy for the treatment of cancers.